Company Overview - N2OFF, Inc. is a drug discovery company that owns 100% of MitoCareX Bio Ltd., which focuses on developing small-molecule drugs targeting human mitochondrial carriers for inflammatory metabolic diseases [6] - N2OFF is also investing in solar energy assets through a Ready to Build (RTB) business model, currently leading four solar projects across three EU countries [6] MitoCareX Bio Developments - MitoCareX Bio has demonstrated preliminary in vitro data showing inhibition of pro-inflammatory responses in human immune cells using its proprietary MITOLINE discovery platform [1][2] - The company is advancing its most promising mitochondrial-targeted anti-inflammatory candidates toward pre-clinical studies while expanding the MITOLINE-powered discovery engine across additional mitochondrial carrier targets [5] Market Potential - The global market for anti-inflammatory drugs is projected to grow from approximately $122 billion in 2024 to nearly $275 billion by 2034, with a compound annual growth rate (CAGR) of about 8.4% [3] - Small-molecule immunomodulators are expected to expand from around $188 billion in 2025 to over $350 billion by 2035, indicating strong demand for targeted anti-inflammatory therapies [3] - Therapeutics for metabolic disorders, including key inflammatory metabolic diseases, are estimated to be around $77 billion in 2024 and forecasted to exceed $120 billion by 2030 [3] MITOLINE Algorithm - The MITOLINE algorithm addresses a critical bottleneck in mitochondrial drug discovery by providing reliable 3D comparative models of mitochondrial carrier proteins, facilitating the identification of novel small-molecule scaffolds [4] - This platform enables MitoCareX to characterize substrate translocation binding sites for virtual screening campaigns, supporting drug discovery in oncology, autoimmune, and metabolic-inflammatory diseases [4]